A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: The DARAD trial

International Journal of Geriatric Psychiatry

Volumn 28, Issue 5, 2013, Pages 463-470

  Molloy, D William ^a   Standish, T I ^b   Zhou, Q ^b   Guyatt, G ^b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; doxycycline; randomized; rifampin; trial

Indexed keywords

DOXYCYCLINE; PLACEBO; RIFAMPICIN;

AGED; ALZHEIMER DISEASE; ANEMIA; ARTICLE; BEHAVIOR DISORDER; CANADA; CARDIOVASCULAR DISEASE; CLINICAL DEMENTIA RATING; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DETERIORATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FACTORIAL DESIGN; FEMALE; GASTROINTESTINAL SYMPTOM; GERIATRIC DEPRESSION SCALE; HUMAN; HYPERLIPIDEMIA; HYPOKALEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MOOD DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEOPLASM; OUTPATIENT DEPARTMENT; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; UROGENITAL TRACT DISEASE; VISUAL DISORDER; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CANADA; DOXYCYCLINE; DRUG THERAPY, COMBINATION; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PSYCHIATRIC STATUS RATING SCALES; RIFAMPIN; TREATMENT OUTCOME;

EID: 84876131474     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.3846     Document Type: Article

References (27)

1. Aisen PA, Mehran M, Poole R, et al,. 2004. Clinical data on Alzhemed(TM) after 12 months of treatment in patients with mild to moderate Alzheimer's disease. Neurobiol Aging 25: S20.
2. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA,. 1988. Cornell Scale for Depression in Dementia. Biol Psychiatry 23: 271-284.
3. Chang W-P, Koelsch G, Wong S, et al,. 2004. In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J Neurochem 89: 1409-1416.
4. Cherny RA, Atwood CS, Xilinas ME, et al,. 2001. Treatment with a copper-zinc chelator markedly and rapidly inhibits [beta]-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30: 665-676.
5. Etcheberrigaray R, Tan M, Dewachter I, et al,. 2004. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci USA 101: 11141-11146.
6. Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M,. 2001. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 487 (3): 404-407.
7. Lan KKG, Wittes J,. 1987. The B-value: a tool for monitoring data. Biometrics 44: 579-585.
8. Lawton MP, Brody EM,. 1969. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9: 179-186.
9. Levy RH, Collins C,. 2007. Risk and predictability of drug interactions in the elderly. In International Review of Neurobiology-The Neurobiology of Epilepsy and Aging, 81 edn., Eugene Ramsay R, et al. (eds). Academic Press: San Diego, USA; 235-251.
10. Loeb MB, Molloy DW, Smieja M, et al,. 2004. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc 52: 381-387.
11. Milano J, McKay J, Dagenais C, et al,. 2004. Modulation of Notch processing by ?-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 82: 341-358.
12. Molloy DW, Alemayehu E, Roberts RS,. 1991a. Reliability of a standardized mini-mental state examination compared with the traditional mini-mental state examination. Am J Psychiatry 148 (1): 102-105.
13. Molloy DW, McIlroy WE, Guyatt GH, Lever JA,. 1991b. Validity and reliability of the dysfunctional behavior rating instrument. Acta Psychiatr Scand 84: 103-106.
14. Molloy DW, Bédard M, Guyatt GH, Lever J,. 1996. Dysfunctional behaviour rating instrument. Int Psychogeriatr 8 (Suppl 3): 333-341.
15. Molloy DW, Standish TIM, Lewis DL,. 2005. Screening for mild cognitive impairment: comparing the SMMSE and the ABCS. Can J Psychiatry 50: 183-189.
16. Morris JC,. 1993. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43: 2412-2414.
17. O' Caoimh R, Gao Y, McGlade C, et al,. 2012. Comparison of the quick mild cognitive impairment (Qmci) screen and the SMMSE in screening for mild cognitive impairment. Age Ageing DOI: 10.1093/ageing/afs059.
18. Ritchie CW, Bush AI, Mackinnon A, et al,. 2003. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60 (12): 1685-1691.
19. SantaCruz K, Lewis J, Spires T, et al,. 2005. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309: 476-481.
20. Schafer KA, Tractenberg RE, Sano, M, et al,. 2004. Reliability of monitoring the Clinical Dementia Rating in multicenter clinical trials. Alzheimer Dis Assoc Disord 18: 219-222.
21. Schenk D, Barbour R, Dunn W, et al,. 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the DA mouse. Nature 400: 173-177.
22. Scott NW, McPherson GC, Ramsay CR, Campbell MK,. 2002. The method of minimization for allocation to clinical trials: a review. Control Clin Trials 23: 662-674.
23. Standish T, Molloy DW, Bédard M, et al,. 1996. Improved reliability of the standardized Alzheimer's Disease Assessment Scale (SADAS) compared with the Alzheimer's Disease Assessment Scale (ADAS). J Am Geriatr Soc 44 (6): 712-716.
24. Standish TI, Molloy DW, Cunje A, Lewis DL,. 2007. Do the ABCS 135 short cognitive screen and its subtests discriminate between normal cognition, mild cognitive impairment and dementia? Int J Geriatr Psychiatry 22: 189-194.
25. Tomiyama T, Asano S, Suwa Y, et al,. 1994. Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro. Biochem Biophys Res Commun 204: 76-83.
26. Tomiyama T, Shoji A, Kataoka K, et al,. 1996. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J Biol Chem 271: 6839-6844.
27. Yesavage JA,. 1988. Geriatric Depression Scale. Psychopharmacol Bull 24: 709-711.